Policy

ACR Survey Reveals Patient Knowledge Gaps on Biosimilars

September 16th 2020

By Skylar Jeremias

Many patients with rheumatic diseases are unsure whether their prescriptions are biosimilars, suggesting more efforts in patient education are needed.

Expert Opinion Roundup: Overcoming Barriers to Biosimilar Uptake

September 7th 2020

By Skylar Jeremias

This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.

Part 2: Surya Singh, MD, on Whether Biosimilars Will Lower Drug Costs

September 3rd 2020

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.

Samsung Bioepis Exec Discusses European On-Ramp for Aybintio

September 3rd 2020

By Tony Hagen

Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.

Report: OOP Insulin Caps Could Save Money, but Other Factors Bear Watching

September 3rd 2020

By Skylar Jeremias

Authors of a report on Medicare spending trends said there’s more to controlling the affordability of insulin than instituting out-of-pocket (OOP) caps.

Report: PBM "Reforms" Leave Biosimilars Out in the Cold

September 2nd 2020

By Tony Hagen

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

Midwest Business Group on Health Issues Call to Action on Biosimilars

August 28th 2020

By Skylar Jeremias

To help employers achieve biosimilar savings, the Midwest Business Group on Health has created a 13-step action plan.

Short Course on Biosimilar Supportive Care During the Pandemic

August 27th 2020

Julianna Merten, PharmD, BCPS, BCOP, of Mayo Clinic provides an overview of growth factor biosimilars for pharmacists amid the pandemic.

Part 2: Cheryl Larson on What Employers Can Do to Influence Health Plan Decisions

August 27th 2020

Cheryl Larson, president and CEO of the Midwest Business Group on Health, based in Chicago, Illinois, discussed what employers can do to get biosimilars added to their formulary lists and ensure their pharmacy benefit managers (PBMs) aren’t taking advantage of them.

Dan Leonard Takes Helm of Association for Accessible Medicines

August 27th 2020

By Tony Hagen

The Association for Accessible Medicines, which represents generic and biosimilar manufacturers, chose a leader with a research, public relations, and strategic planning background.